Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate Hydrochloride

Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate Hydrochloride

Methyl (4S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride (CAS 3104671-22-6) is the hydrochloride salt of a strained bridged-bicyclic hydrazine ester: a 2,3-diazabicyclo[3.1.1]heptane core in which two adjacent ring nitrogens form an N-N bridge across the bicyclic framework, and the (4S)-configured bridge carbon bears a methyl carboxylate group.
Send Inquiry

English synonyms :Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride

English synonyms:Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride;Methyl (4S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride;2,3-Diazabicyclo[3.1.1]heptane-4-carboxylic acid, methyl ester, hydrochloride (1:1), (4S)-;Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride (HCl salt form)

CAS number :3104671-22-6

Molecular formula : C7H13ClN2O2

Molecular weight :192.64 (free base 156.18)

Properties: White to off-white solid (hydrochloride salt)

Content: ≥98% Professional scientific accurate detection

Function: Used in foreign trade export, scientific research and chemical reagents and other fields; it is employed mainly as a strained bridged-bicyclic hydrazine building block (2,3-diazabicyclo[3.1.1]heptane) that serves as the bridged-ring fragment in the synthesis of RAS(ON) G12V-selective inhibitor RMC-5127 in pharmaceutical research and organic synthesis.

Packing: 1G 100G 500G 1KG

Storage: Dry, sealed, protected from light, stored at 2-8℃, shelf life of 2 years

 

Structural formula:

product-900-700

Methyl (S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride use and synthesis method

 

Intro

Methyl (4S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride (CAS 3104671-22-6) is the hydrochloride salt of a strained bridged-bicyclic hydrazine ester: a 2,3-diazabicyclo[3.1.1]heptane core in which two adjacent ring nitrogens form an N-N bridge across the bicyclic framework, and the (4S)-configured bridge carbon bears a methyl carboxylate group. Key identifiers: free base molecular formula C7H12N2O2, hydrochloride C7H13ClN2O2, molecular weight 192.64 (free base 156.18), SMILES COC(=O)[C@H]1NNC2CC1C2 (free base), InChIKey RFNAYPCGDTXCOM-WRVKLSGPSA-N (free base), IUPAC name methyl (4S)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride (1:1). Commercial material is supplied at minimum 98% purity by fine-chemical building block suppliers.

 

Peculiarity

The compound combines four practical features: (i) a rigid, compact bicyclo[3.1.1]heptane framework carrying an adjacent N-N (hydrazine) unit, giving a dense, three-dimensional sp3-rich scaffold that projects substituents in well-defined vectors; (ii) an (4S)-configured stereocentre bearing the methyl ester, which fixes the stereochemical presentation of the fragment during assembly of larger molecules; (iii) the hydrochloride salt form, which stabilises the bridged amine and simplifies handling, weighing and storage relative to the volatile free base; (iv) a chemically versatile ester handle that can be hydrolysed to the parent acid, aminolysed to amides, or carried forward after N-deprotection. Material is stored sealed and dry at 2-8°C.

 

Uses

This compound is a synthetic intermediate, not a drug substance, and has no pharmacological activity of its own. The 2,3-diazabicyclo[3.1.1]heptane unit is the characteristic bridged ring of RMC-5127, Revolution Medicines' RAS(ON) G12V-selective inhibitor, which binds cyclophilin A to create a complex that selectively recognises and inhibits the oncogenic, GTP-bound RAS G12V variant; the first patient was dosed in January 2026 in the first-in-human Phase 1/1b study of RMC-5127. Indications and population: RMC-5127 is being developed for advanced (metastatic) KRAS G12V-mutant solid tumours, predominantly pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC); the intended patient population is adults with advanced KRAS G12V-mutant solid tumours who have progressed on, or are intolerant to, prior standard therapies including targeted treatments. KRAS G12V is the second most common oncogenic RAS mutation, with an estimated 48,000 patients diagnosed each year in the United States, and no targeted therapy is approved for it; RMC-5127 remains investigational.

 

Synthesis and representative transformations

The 2,3-diazabicyclo[3.1.1]heptane ring system is assembled by intramolecular cyclisation strategies that construct the cyclobutane-fused hydrazine framework with the nitrogen-nitrogen bond already in place; the two nitrogens are carried through the sequence in protected form (Boc or equivalent), and the (4S)-configured carboxylate is introduced at the stereogenic centre and elaborated to the methyl ester. Treatment of the free base with hydrogen chloride in ether or 1,4-dioxane furnishes the crystalline hydrochloride salt. The salt and the corresponding 2,3-bis(Boc)-protected acid (CAS 3034241-44-3) are the two standard protected forms of this bridged fragment and are interconvertible by standard deprotection, esterification and salt-formation sequences.

Starting materials: protected hydrazine precursors bearing the N-N bond for ring assembly; the corresponding 2,3-bis(tert-butoxycarbonyl)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylic acid (CAS 3034241-44-3) as the protected acid precursor.

Reagents and conditions: hydrogen chloride in ether or 1,4-dioxane for hydrochloride salt formation; TFA or HCl/dioxane for Boc removal; methanol under acid catalysis for methyl esterification; purification by crystallisation or trituration.

Representative transformations: hydrolysis of the methyl ester to the parent (4S)-acid; amide coupling or ester aminolysis to attach the bridged fragment to amines; N-deprotection of the hydrazine unit followed by N-alkylation or N-acylation.

Yields and specifications: commercial material is specified at minimum 98% purity; white to off-white solid; store sealed and dry at 2-8°C.

Hot Tags: methyl (s)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride, China methyl (s)-2,3-diazabicyclo[3.1.1]heptane-4-carboxylate hydrochloride suppliers, 20099-89-2, 204254-96-6, Dalbavancin HCL, Isavuconazonium Sulfate Intermediate Novel Antifungal, pharmaceutical biochemistry, Rocuronium bromide intermediate